glp 1 drugs shortage FDA's GLP-1 decision kicks off 'unprecedented' tussle over glp 1 drugs shortage Hims:

Records were initially screened at title and abstract level, and potentially eligible records were examined in full text with reasons for exclusion being recorded

Interestingly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), used in the treatment of T2DM and obesity, are known to show pro-cognitive and neuroprotective properties, and exert modulatory effects on immune, endocrine and metabolic processes in the central nervous system

Wadden TA, Chao AM, Machineni S, et al

10.1007/s40265-017-0694-4 [DOI] [PubMed] [Google Scholar] 83.Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC

Fujita H, Taniai H, Murayama H, et al

Furthermore, A 36-week randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of NLY01 in patients with early, untreated Parkinsons disease